GNRH1 and endometriosis: In the context of endometriosis, relugolix combination therapy has demonstrated superiority over placebo and non-inferiority to injectable GnRH agonists in alleviating pain symptoms, including dysmenorrhea, non-menstrual pelvic pain, and dyspareunia.